All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ibudilast 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antiasthmatics or antiallergics, not acting primarily as antihistaminics anti-allergic or anti-inflammatory, not acting as anti-histaminics	1406	50847-11-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ketas KP-305 ibudilast	Molecular weight: 230.31 Formula: C14H18N2O CLOGP: 3.41 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 34.37 ALOGS: -3.11 ROTB: 3

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP3K21,MAPK7,MARK4,NTRK2,PDK1,PDK2,PIK3CD,PRKDC,SIK2,STK33,TEK,TTK	27
kinase-selectivity-class	AXL,BRAF	2
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
May 1, 1989	PMDA	Kyorin Pharmaceutical

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Body tinea	294.26	236.92	45	988	2103	90625311
Inhibitory drug interaction	269.69	236.92	44	989	3119	90624295
Infection susceptibility increased	267.14	236.92	45	988	3881	90623533
Poor quality sleep	258.36	236.92	59	974	24634	90602780

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Body tinea	293.77	137.66	44	1045	2071	110586139
Infection susceptibility increased	261.58	137.66	44	1045	4354	110583856
Inhibitory drug interaction	249.58	137.66	43	1046	4904	110583306
Poor quality sleep	248.51	137.66	57	1032	28020	110560190
Glucose tolerance impaired	226.21	137.66	44	1045	9793	110578417
Bone density decreased	204.75	137.66	44	1045	15998	110572212
Impaired quality of life	202.82	137.66	49	1040	29968	110558242
Impaired work ability	198.52	137.66	47	1042	26372	110561838
Purpura	196.95	137.66	46	1043	24342	110563868
Hyperlipidaemia	169.56	137.66	44	1045	35804	110552406
Oral herpes	169.28	137.66	44	1045	36036	110552174
Skin disorder	161.71	137.66	44	1045	42869	110545341
Cataract	139.02	137.66	45	1044	79440	110508770

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R03DC04	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Leukotriene receptor antagonists
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D010726	Phosphodiesterase Inhibitors
MeSH PA	D010975	Platelet Aggregation Inhibitors
MeSH PA	D014665	Vasodilator Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D019141	Respiratory System Agents
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35705	immunosuppressive agent
CHEBI has role	CHEBI:149553	anticoronaviral agent

Related Drugs by ATC class:

R03DC Leukotriene receptor antagonists 3 drugs

montelukastpranlukastzafirlukast

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Asthma	indication	195967001	DOID:2841

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.86	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Enzyme	Q14432	PDE3A_HUMAN		IC50	5.80		CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Enzyme	Q07343	PDE4B_HUMAN		IC50	7.19		CHEMBL
cGMP-specific 3',5'-cyclic phosphodiesterase	Enzyme	O76074	PDE5A_HUMAN		IC50	5.46		CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Enzyme	P27815	PDE4A_HUMAN		IC50	7.27		CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Enzyme	Q08499	PDE4D_HUMAN		IC50	6.78		CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4C	Enzyme	Q08493	PDE4C_HUMAN		IC50	6.62		CHEMBL
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Enzyme	Q13370	PDE3B_HUMAN		IC50	5.57		CHEMBL
Macrophage migration inhibitory factor	Cytokine	P14174	MIF_HUMAN		Kd	5.85		CHEMBL

External reference:

ID	Source
D01385	KEGG_DRUG
C0123047	UMLSCUI
CHEBI:31684	CHEBI
CHEMBL19449	ChEMBL_ID
DB05266	DRUGBANK_ID
CHEMBL395091	ChEMBL_ID
3671	PUBCHEM_CID
C038366	MESH_SUPPLEMENTAL_RECORD_UI
7399	IUPHAR_LIGAND_ID
6068	INN_ID
M0TTH61XC5	UNII
010937	NDDF
AVL	PDB_CHEM_ID
M0TTH61XC5	INXIGHT DRUGS

Pharmaceutical products:

None